Cargando…

Replication and immune response in HAE of HCoV-HKU1 isolate from a pediatric patient with severe acute respiratory infection

Detalles Bibliográficos
Autores principales:	Zhu, N., Lu, R.J., Tan, W.J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Published by Elsevier B.V. 2016
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129603/ http://dx.doi.org/10.1016/j.jcv.2016.08.227

Ejemplares similares

Human Coronaviruses HCoV-NL63 and HCoV-HKU1 in Hospitalized Children with Acute Respiratory Infections in Beijing, China
por: Cui, Li-Jin, et al.
Publicado: (2011)

Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)
por: Dugas, Martin, et al.
Publicado: (2021)

Origins of HIV, HCoV-HKU1, SFTSV, and MERS-CoV and Beyond
por: Liu, Wenli, et al.
Publicado: (2022)

Épidémiologie des infections à coronavirus HCoV-HKU1 à Marseille, France
por: Ninove, L., et al.
Publicado: (2020)

Human Coronavirus Infections in Israel: Epidemiology, Clinical Symptoms and Summer Seasonality of HCoV-HKU1
por: Friedman, Nehemya, et al.
Publicado: (2018)

Coronavirus humains (HCoV)
por: Vabret, A., et al.
Publicado: (2009)

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2012)

Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study
por: Aldridge, Robert W., et al.
Publicado: (2020)

Titration of Human Coronaviruses, HCoV-229E and HCoV-OC43, by an Indirect Immunoperoxidase Assay
por: Lambert, Francine, et al.
Publicado: (2007)

Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host
por: Forni, Diego, et al.
Publicado: (2021)

Epidemiology of respiratory coronaviruses (HCoV) in a Dutch university hospital
por: Niesters, H.G.M., et al.
Publicado: (2006)

Inhibition of HCoV-NL63 infection at early stages of the replication cycle
por: van der Hoek, L., et al.
Publicado: (2006)

Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43
por: Fuochi, Virginia, et al.
Publicado: (2023)

HCoV-229E Infects and Activates Monocytes
por: Desforges, Marc, et al.
Publicado: (2006)

Seroconversion to HCoV-NL63 in Rhesus Macaques
por: Dijkman, Ronald, et al.
Publicado: (2009)

HCoV-OC43–Induced Encephalitis is in Part Immune-Mediated
por: Butler, Noah, et al.
Publicado: (2006)

Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2
por: Liu, Donglan, et al.
Publicado: (2023)

Understanding Human Coronavirus HCoV-NL63
por: Abdul-Rasool, Sahar, et al.
Publicado: (2010)

Novel polymeric inhibitors of HCoV-NL63
por: Milewska, Aleksandra, et al.
Publicado: (2013)

Structural characterization of the HCoV-229E fusion core
por: Zhang, Wei, et al.
Publicado: (2018)

Resveratrol Inhibits HCoV-229E and SARS-CoV-2 Coronavirus Replication In Vitro
por: Pasquereau, Sébastien, et al.
Publicado: (2021)

HCoV-Oc43–Induced Apoptosis of Murine Neuronal Cells
por: Jacomy, Hélène, et al.
Publicado: (2006)

Corrigendum to ’Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506’ Virus Research (2012) 165/1 [112-117]: Corrigendum
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2022)

Baculovirus expression of HCoV-OC43 nucleocapsid protein and development of a Western blot assay for detection of human antibodies against HCoV-OC43
por: Mourez, Thomas, et al.
Publicado: (2007)

Improving human coronavirus OC43 (HCoV-OC43) research comparability in studies using HCoV-OC43 as a surrogate for SARS-CoV-2
por: Schirtzinger, Erin E., et al.
Publicado: (2022)

Pan-Coronavirus CRISPR-CasRx Effector System Significantly Reduces Viable Titer in HCoV-OC43, HCoV-229E, and SARS-CoV-2
por: Mayes, Cathryn M., et al.
Publicado: (2023)

The human coronavirus HCoV-229E S-protein structure and receptor binding
por: Li, Zhijie, et al.
Publicado: (2019)

Human Coronavirus (HCoV) Infection Among Adults in Cleveland, Ohio: An Increasingly Recognized Respiratory Pathogen
por: Kanwar, Anubhav, et al.
Publicado: (2017)

Ferulic acid derivatives block coronaviruses HCoV-229E and SARS-CoV-2 replication in vitro
por: Pasquereau, Sébastien, et al.
Publicado: (2022)

Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia
por: Lynch, Sean A., et al.
Publicado: (2021)

Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator
por: Chen, Yongkang, et al.
Publicado: (2022)

Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein
por: Xiang, Jiangchao, et al.
Publicado: (2022)

HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients
por: Steiner, Sophie, et al.
Publicado: (2020)

Genetic tracing of HCoV-19 for the re-emerging outbreak of COVID-19 in Beijing, China
por: Yang, Jing, et al.
Publicado: (2020)

The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection
por: Santacroce, Luigi, et al.
Publicado: (2020)

Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex
por: Feng, Yongmei, et al.
Publicado: (2022)

Inhibition by components of Glycyrrhiza uralensis of 3CLpro and HCoV-OC43 proliferation
por: Kim, Jang Hoon, et al.
Publicado: (2023)

Co-circulation of Four Human Coronaviruses (HCoVs) in Queensland Children with Acute Respiratory Tract Illnesses in 2004
por: Mackay, Ian M., et al.
Publicado: (2012)

Targeting the m(6)A RNA modification pathway blocks SARS-CoV-2 and HCoV-OC43 replication
por: Burgess, Hannah M., et al.
Publicado: (2021)

SNAP@CQD as a promising therapeutic vehicle against HCoVs: An overview
por: Chatterjee, Satyaki, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_4le8uv88rs73tmv4jmlhru7fji